Newly Developed Drugs for Hepatocellular Carcinoma Expanded the Use of Systemic Therapy: An Interrupted Time Series Analysis Using an Electronic Medical Record in Japan
Newly developed drugs for HCC would expand the population for systemic therapy. The optimal population for systemic therapy should be explored based on long-term survival considering age and liver functional reserve heterogeneity.
Authors
- Koji Kawakami (ORCID: https://orcid.org/0000-0002-7477-4071)
- Takanori Yanai (ORCID: https://orcid.org/0009-0005-8558-4950)
- Sachiyo Shirakawa
Institutions
- Kyoto University (JP)
- AstraZeneca (Japan) (JP)
Publication Details
- Journal
- Oncology
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1159/000547883
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00